We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Corcept Therapeutics (CORT - Free Report) . Shares have added about 9.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Corcept Q3 Earnings & Revenues Lag Estimates, 2025 View Cut
Corcept reported third-quarter 2025 earnings of 16 cents per share, which missed the Zacks Consensus Estimate of 18 cents. The company had reported earnings of 41 cents per share in the year-ago quarter.
Revenues in the third quarter increased around 14% year over year to $207.6 million. The figure, however, missed the Zacks Consensus Estimate of $219 million. The top line solely comprised product sales of the Cushing’s syndrome drug, Korlym.
Quarter in Detail
Revenues from Korlym missed our model estimate of $222.6 million.
Research and development expenses rose 16% year over year to $68.8 million.
Selling, general and administrative expenses increased around 68.2% year over year to $124 million.
Consequently, operating expenses increased 30.8% year over year to $197.4 million in the third quarter.
Cash and investments, as of Sept 30, 2025, totaled $524.2 million compared with $515 million as of June 30, 2025.
2025 Guidance
Corcept lowered its total revenue guidance for 2025.
For the full-year 2025, the company now expects total revenues in the range of $800-$850 million compared with the earlier projection of $850-$900 million.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -36.91% due to these changes.
VGM Scores
Currently, Corcept has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Corcept has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Corcept is part of the Zacks Medical - Drugs industry. Over the past month, United Therapeutics (UTHR - Free Report) , a stock from the same industry, has gained 7.5%. The company reported its results for the quarter ended September 2025 more than a month ago.
United Therapeutics reported revenues of $799.5 million in the last reported quarter, representing a year-over-year change of +6.8%. EPS of $7.16 for the same period compares with $6.39 a year ago.
United Therapeutics is expected to post earnings of $6.74 per share for the current quarter, representing a year-over-year change of +8.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.8%.
United Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Corcept Therapeutics (CORT - Free Report) . Shares have added about 9.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Corcept Q3 Earnings & Revenues Lag Estimates, 2025 View Cut
Corcept reported third-quarter 2025 earnings of 16 cents per share, which missed the Zacks Consensus Estimate of 18 cents. The company had reported earnings of 41 cents per share in the year-ago quarter.
Revenues in the third quarter increased around 14% year over year to $207.6 million. The figure, however, missed the Zacks Consensus Estimate of $219 million. The top line solely comprised product sales of the Cushing’s syndrome drug, Korlym.
Quarter in Detail
Revenues from Korlym missed our model estimate of $222.6 million.
Research and development expenses rose 16% year over year to $68.8 million.
Selling, general and administrative expenses increased around 68.2% year over year to $124 million.
Consequently, operating expenses increased 30.8% year over year to $197.4 million in the third quarter.
Cash and investments, as of Sept 30, 2025, totaled $524.2 million compared with $515 million as of June 30, 2025.
2025 Guidance
Corcept lowered its total revenue guidance for 2025.
For the full-year 2025, the company now expects total revenues in the range of $800-$850 million compared with the earlier projection of $850-$900 million.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -36.91% due to these changes.
VGM Scores
Currently, Corcept has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Corcept has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Corcept is part of the Zacks Medical - Drugs industry. Over the past month, United Therapeutics (UTHR - Free Report) , a stock from the same industry, has gained 7.5%. The company reported its results for the quarter ended September 2025 more than a month ago.
United Therapeutics reported revenues of $799.5 million in the last reported quarter, representing a year-over-year change of +6.8%. EPS of $7.16 for the same period compares with $6.39 a year ago.
United Therapeutics is expected to post earnings of $6.74 per share for the current quarter, representing a year-over-year change of +8.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.8%.
United Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.